CINECA IRIS Institutional Research Information System

CIABATTI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.232
AS - Asia 1.946
EU - Europa 1.895
SA - Sud America 325
Continente sconosciuto - Info sul continente non disponibili 163
AF - Africa 107
OC - Oceania 2
Totale 8.670
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.102
IT - Italia 605
SG - Singapore 603
CN - Cina 600
SE - Svezia 412
HK - Hong Kong 282
BR - Brasile 274
DE - Germania 223
VN - Vietnam 197
GB - Regno Unito 186
BG - Bulgaria 135
CA - Canada 98
FR - Francia 87
FI - Finlandia 72
TR - Turchia 69
RU - Federazione Russa 60
CI - Costa d'Avorio 46
JP - Giappone 45
IN - India 44
BE - Belgio 24
UA - Ucraina 24
BD - Bangladesh 18
SN - Senegal 15
UZ - Uzbekistan 13
ES - Italia 12
ZA - Sudafrica 12
AR - Argentina 11
EC - Ecuador 10
IQ - Iraq 10
NL - Olanda 10
PL - Polonia 10
MX - Messico 9
SA - Arabia Saudita 9
VE - Venezuela 9
KR - Corea 8
NG - Nigeria 8
CO - Colombia 7
CZ - Repubblica Ceca 7
LT - Lituania 7
PK - Pakistan 7
ID - Indonesia 6
MA - Marocco 6
CL - Cile 5
IL - Israele 5
KE - Kenya 5
KZ - Kazakistan 5
AE - Emirati Arabi Uniti 4
DO - Repubblica Dominicana 4
EG - Egitto 4
GR - Grecia 4
PH - Filippine 4
AT - Austria 3
CH - Svizzera 3
ET - Etiopia 3
HN - Honduras 3
IE - Irlanda 3
IR - Iran 3
JM - Giamaica 3
JO - Giordania 3
PY - Paraguay 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
UY - Uruguay 3
AU - Australia 2
BS - Bahamas 2
DZ - Algeria 2
EU - Europa 2
HR - Croazia 2
KW - Kuwait 2
MD - Moldavia 2
MY - Malesia 2
PE - Perù 2
PR - Porto Rico 2
PS - Palestinian Territory 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BB - Barbados 1
BJ - Benin 1
BM - Bermuda 1
CR - Costa Rica 1
DK - Danimarca 1
HU - Ungheria 1
LY - Libia 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SR - Suriname 1
SV - El Salvador 1
TG - Togo 1
Totale 8.511
Salva come PNG Salva come JPEG
Città #
Ashburn 458
Singapore 310
Dallas 302
Serra 275
Santa Clara 273
Fairfield 272
Hong Kong 272
Woodbridge 270
San Jose 255
Chandler 237
Houston 211
Ann Arbor 205
Beijing 159
Sofia 131
Seattle 128
Shanghai 118
New York 111
Wilmington 102
Boardman 89
Cambridge 85
Los Angeles 76
Council Bluffs 72
Princeton 70
Ottawa 67
Milan 58
London 56
Munich 53
Medford 47
Abidjan 46
Lauterbourg 46
Lawrence 44
Florence 43
Ho Chi Minh City 40
Des Moines 37
Hanoi 36
Tokyo 35
Lancaster 30
Bremen 27
Dearborn 27
Izmir 27
Pisa 26
Istanbul 23
Nanjing 23
San Diego 23
Brussels 22
Helsinki 22
São Paulo 22
Jacksonville 20
Redondo Beach 20
Rome 18
Dakar 15
Dong Ket 15
Frankfurt am Main 15
Hefei 15
Turku 14
Buffalo 13
Shenyang 13
Tashkent 13
Nanchang 12
Orem 12
Phoenix 12
Chicago 11
Fuzhou 11
Montreal 11
Toronto 11
Alessandria 10
Atlanta 10
Düsseldorf 10
Brooklyn 9
Changsha 9
Hebei 9
Nuremberg 9
Redwood City 9
Rio de Janeiro 9
Warsaw 9
Washington 9
Boston 8
Campinas 8
Duncan 8
Kunming 8
Monza 8
Denver 7
Lagos 7
The Dalles 7
Chennai 6
Columbus 6
Johannesburg 6
Kocaeli 6
Ogden 6
San Francisco 6
Stockholm 6
Ankara 5
Da Nang 5
Detroit 5
Falkenstein 5
Guangzhou 5
Haiphong 5
Hangzhou 5
Jiaxing 5
Manchester 5
Totale 5.862
Salva come PNG Salva come JPEG
Nome #
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 282
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study 279
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 252
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 242
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 219
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 219
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 210
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 207
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 206
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 206
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 201
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 197
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 197
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 197
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 190
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 189
MDS: An Integrated Workup for a Correct Diagnosis 187
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 185
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 183
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 182
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 179
LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES 173
Donor-transmitted Triple-Hit Lymphoma in a Renal Allograft Recipient 171
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 170
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 169
Combined FAMD and ANOVA investigation leads to significant association between the hOCT1/ABCB1 diplotype and both efficacy and tolerability in patients affected by chronic myeloid leukemia 166
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice 166
Molecular detection of GNNK- and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia 165
Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS) 161
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 157
TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION OF POLYCOMB GENES IN CHRONIC MYELOID LEUKEMIA 154
Conventional Cytogenetics, ACGH, and PCR as Integrated Workup for a Correct Diagnosis of MDS 152
WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes 151
Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation 151
Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation 151
R-IPSS, RPS14 AND WT1 LEVELS ARE THE BEST PROGNOSTIC FACTORS FOR PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES DURING AZACITIDINE TREATMENT. 147
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation 141
Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line 140
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 138
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation 136
THE C.480C>G POLYMORPHISM OF HOCT1 TRANSPORTER INFLUENCES IMATINIB CLEARANCE IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 132
Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification 132
Cell clonality in hypereosinophilic syndrome: what pathogenetic role? 119
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms 114
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study 109
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 105
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.sinensis leaf extract. 98
Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network 95
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms 89
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: Correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 88
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 87
Human mesenchymal cells inhibit IL2 and zoledronate-induced gamma/delta T-cells 83
null 51
Totale 8.670
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.861
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.861
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022623 0 0 12 39 111 92 24 17 70 28 53 177
2022/2023863 133 164 53 72 71 94 8 67 124 15 57 5
2023/2024494 55 39 66 31 52 86 28 12 6 19 24 76
2024/20251.731 6 60 11 99 198 202 174 114 145 218 178 326
2025/20262.117 136 247 285 218 213 179 336 112 108 194 62 27
2026/2027196 39 122 35 0 0 0 0 0 0 0 0 0
Totale 8.670